Alasdair P S Munro
Overview
Explore the profile of Alasdair P S Munro including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
1588
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Paulson S, Munro A, Cathie K, Bedford H, Jones C
Pediatr Infect Dis J
. 2025 Feb;
44(2S):S158-S161.
PMID: 39951096
Background: Maternal vaccination and infant monoclonal antibodies are promising avenues to protect young infants from respiratory syncytial virus (RSV) infection. Successful inclusion into the UK immunization schedule depends on parental...
2.
Munro A, Jones C, Faust S
Eur J Pediatr
. 2024 Jan;
183(3):1107-1112.
PMID: 38169007
Countries in Europe and around the world have taken varying approaches to their policies on COVID-19 vaccination for children. The low risk of severe illness from COVID-19 means that even...
3.
Munro A, Martinon-Torres F, Drysdale S, Faust S
Curr Opin Infect Dis
. 2023 Aug;
36(5):379-384.
PMID: 37610444
Purpose Of Review: To describe the current global burden of respiratory syncytial virus (RSV) in infants and its implications for morbidity, health resources and economic costs. Recent Findings: New prophylactic...
4.
Zhu Y, Almeida F, Baillie J, Bowen A, Britton P, Brizuela M, et al.
JAMA Pediatr
. 2023 Aug;
177(10):1073-1084.
PMID: 37603343
Importance: Multiple SARS-CoV-2 variants have emerged over the COVID-19 pandemic. The implications for COVID-19 severity in children worldwide are unclear. Objective: To determine whether the dominant circulating SARS-CoV-2 variants of...
5.
6.
Liu X, Munro A, Wright A, Feng S, Janani L, Aley P, et al.
J Infect
. 2023 Apr;
87(1):18-26.
PMID: 37085049
Background: COV-BOOST is a multicentre, randomised, controlled, phase 2 trial of seven COVID-19 vaccines used as a third booster dose in June 2021. Monovalent messenger RNA (mRNA) COVID-19 vaccines were...
7.
Munro A, Hungwe C, Patel P, Ward N, Struthers S, Saeed K
Infez Med
. 2022 Dec;
30(4):587-592.
PMID: 36482951
Objective: Febrile illnesses are a common cause of presentation in acute pediatrics, with biomarkers frequently used to help differentiate mild infections from serious bacterial infections (SBI). We aimed to see...
8.
9.
Lazarus R, Taucher C, Brown C, Ramljak I, Danon L, Dubischar K, et al.
J Infect
. 2022 Jun;
85(3):306-317.
PMID: 35718205
Objectives: We aimed to evaluate the safety and optimal dose of a novel inactivated whole-virus adjuvanted vaccine against SARS-CoV-2: VLA2001. Methods: We conducted an open-label, dose-escalation study followed by a...
10.
Munro A, Feng S, Janani L, Cornelius V, Aley P, Babbage G, et al.
Lancet Infect Dis
. 2022 May;
22(8):1131-1141.
PMID: 35550261
Background: Some high-income countries have deployed fourth doses of COVID-19 vaccines, but the clinical need, effectiveness, timing, and dose of a fourth dose remain uncertain. We aimed to investigate the...